Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)
- Conditions
- Melanoma
- First Posted Date
- 2015-10-12
- Last Posted Date
- 2015-12-17
- Lead Sponsor
- BioVex Limited
- Target Recruit Count
- 3
- Registration Number
- NCT02574260
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
- Conditions
- Melanoma
- Interventions
- Drug: Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)Biological: Talimogene Laherparepvec
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- BioVex Limited
- Target Recruit Count
- 31
- Registration Number
- NCT01368276
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
- Conditions
- Squamous Cell CarcinomaHead and Neck Cancer
- Interventions
- First Posted Date
- 2010-07-13
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- BioVex Limited
- Target Recruit Count
- 5
- Registration Number
- NCT01161498
- Locations
- 🇺🇸
Investigative Clinical Research of Indiana, Indianapolis, Indiana, United States
🇺🇸James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
- Conditions
- Melanoma
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- BioVex Limited
- Target Recruit Count
- 437
- Registration Number
- NCT00769704
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸University of California San Diego, Moores Cancer Center, La Jolla, California, United States
Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- BioVex Limited
- Target Recruit Count
- 17
- Registration Number
- NCT00402025
- Locations
- 🇺🇸
UCI Medical Center, Orange, California, United States
🇺🇸California Pacific Medical Center, San Francisco, California, United States
🇺🇸Mary Crowely Medical Research Center, Dallas, Texas, United States
- Prev
- 1
- 2
- Next